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Domino Liver transplant (DLT) is a strategy to address organ shortage and expand the liver
donor pool for liver transplantation. Despite offering some unique technical challenges, DLT
appears to be a safe and reasonable option to be considered for selected patients who would
otherwise not benefit from liver transplantation. However, the benefit of expanding the donor
pool must be balanced against the risk of disease transmission.In this review, we present
where the DLT currently stands worldwide and our own experience with this procedure.
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INTRODUCTION
Orthotopic Liver transplantation (OLT) is an important therapeutic option
for patients in a variety of acute and chronic liver diseases. However, the
number of organs available for transplant is not enough to supply the
demands of the ever increasing waiting list (1,2,3). Domino Liver transplant
(DLT) is a strategy to address organ shortage and expand the liver donor pool
for liver transplantation (4,5).
This technique was first performed in 1994, in Portugal and allows the
explanted liver from one patient to be used in another patient (6,7). The 
rationale behind this is that some metabolic disorders which can be corrected by
liver transplantation leave a structurally normal and well-functioning liver that
can be used in another patient (8,9,10).
Familial amyloid polyneuropathy (FAP) is an autosomal-dominant 
hereditary systemic disease that leads to progressive sensory-motor
polyneuropathy (11,12).
Transthyretin (TTR) protein is primarily synthesized in the liver and 
mutations in TTR gene leads to the formation, aggregation and 
accumulation of insoluble amyloid fibrils in other organs. To date, over 120
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TTR mutation have been described, the most common
being the Val30Met mutation (13,14). The deposition
of amyloid fibrils leads to progressive loss of superficial
sensation, severe autonomic dysfunctions, and cardiac
conduction disturbances (15,16).
Since over 90% of TTR Met 30 is produced within
the liver, LT will halt disease progression and clinical
manifestations (17,18,19).
FAP livers have a normal anatomy and show no
abnormal function other than producing variant TTR.
FAP patients are usually young, which in combination
with a short cold ischemia time, allows excellent 
conditions for the liver to be used as a graft (10,20).
Medical treatment of patients with TTR mutation-
FAP involves disease-modifying targeted therapy to 
prevent further production of amyloid deposits
(21,22). Tafamidis, the most commonly used drug,
kinetically stabilizes mutant TTR tetramers and 
prevents their dissociation into monomers. However,
although there is evidence for its effectiveness 
in delaying neurological impairment, Tafamidis does
not seem to halt the progression of FAP entirely.
Therefore,liver transplantation (LT) remains a valid
treatment option for many patients (15,23,24).
Indications for DLT vary between countries and
must take into account factors including age, poten-
tial hazards, probability of recurrence, prognosis and
priorities in the transplant waiting lists. Many 
centers select older and more marginal transplant
candidates for DLT (25). By December 31, 2017, a
total of 1254 domino transplantations were regis-
tered in FAP World Transplant Registry.  Mean domino
recipient age was 55.7 ± 10.2 years, with a median of
57.1 years. Main indications for the DLT recipients
included: primary hepatic malignancy (41.4%), alco-
holic cirrhosis (19%), cirrhosis secondary to hepatitis B
and/or C (17%), metastatic hepatic malignancy (2.3%)
and retransplantation (5.3%). (http://www.fapwtr.org)
It is important that the domino recipient is aware of
the possibility of developing “de novo” FAP disease.
Patients must be assured that, if necessary, they will
have the opportunity to receive a cadaveric graft 
after wards (26,27).
Classic DLT involves resection of the inferior vena
cava (IVC) in the FAP patient, which requires venove-
nous bypass, because FAP patients are particularly 
sensitive to hemodynamic changes after caval 
clamping. In Lisbon, Pena and Barroso developed the
‘Double Piggy-back’ technique, that allows preservation
of the donor´s IVC without the need of caval clamping
or bypass. This technique was first performed by our
group in 2001 (28).
The fundamental rule in total hepatectomy in the
PAF patient is to avoid unnecessary mobilizations that
may contribute to small periods of warm ischemia.  The
hilum is minimally dissected, and the common bile duct
is divided at its mid length. Cholecystectomy is also 
performed. Then, the liver is mobilized and freed from
the IVC. Accessory hepatic veins greater than 5 mm in
diameter are preserved if clamping results in conges-
tion of part of the liver. The right hepatic vein (RHV) and
the cuff of middle (MHV) and left hepatic (LHV) veins
are isolated. After dissection, the proper hepatic artery
is divided at the bifurcation of gastroduodenal and
common hepatic arteries, and the portal vein is divided
1cm below its bifurcation. The RHV is transected close
to the liver parenchyma using a vascular stapler. The 
isolated M-LHV cuff is double clamped and hepatic
veins are then divided close to the liver surface, 
completing total hepatectomy. The explanted liver is
then perfused with preservation solution through the
portal vein and the hepatic artery after opening the
RHV stapler line (28,29).
The “Double Piggy-back” technique offers unique
technical challenges, since vessels are shared between
the donor and the FAP graft. To overcome the problem
of short vascular stumps, many techniques of outflow
reconstruction of the domino graft have been reported.
Graft options to create a “neo” suprahepatic IVC
include the use of a cadaveric IVC with or without renal
vein, iliac veins, and pulmonary artery, among others.
The reconstruction will allow the surgeon to perform
the domino liver transplant in a standard piggyback
fashion (30,31,32) (fig. 1).
DLT is not associated with a higher morbidity or
mortality rate in the donor. However, the recipient 
carries the risk of developing “de novo” FAP disease
(33,34).
Early in the development of the technique and
according to the natural history of FAP disease, it was
assumed that the development of the disease would
only become clinically apparent 25 or 30 years after
DLT. However, there were concerns about the impact of
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the recipient’s age and post-transplant immuno-
suppression on the underlying biological mechanisms
and their possible contribution to the earlier develop-
ment of symptoms in DLT recipient (34,35). Indeed, 
several subsequent papers described the development
of acquired FAP earlier than previously anticipated
(26,28,36). In one study from France, 4 of the 91
patients (4.5%) who underwent a DLT with a FAP liver
developed “de novo” amyloid polyneuropathy proven
by nerve biopsy after a mean delay of 5.75 years (37). 
A Spanish study describes “de novo” amyloidosis
appearing 6-8 years after DLT in 4 out of 31 patients
(12.9%). One study from Portugal by our own group,
reports that 13 of the 114 patients (11.4%) submitted
to DLT developed “de novo“ amyloidosis with a median
elapsed time until the appearance of clinical features of
75 months (60–121 months) (28,38).
Domino recipients should be maintained on lifelong
follow-up and consideration of standardized screening
protocols for acquired amyloid in DLT recipients are 
warranted to develop a management strategy for “de
novo” amyloid polyneuropathy (39). Once iatrogenic
amyloid neuropathy and systemic amyloidosis are 
diagnosed, treatment options are limited and 
retransplantation with a non-domino liver should be
considered. However, retransplantation is considered
to be a high-risk procedure, due to the comorbidities 
of patients and the surgical challenges in an already
transplanted patient (26,36,40).
While the risks of DLT are unique, several studies
suggest that they do not contribute to an elevated 
mortality rate as compared to receiving organs from
deceased donors. In the Domino Liver World Transplant
Register, the overall 1-year, 5-year, and 8-year graft 
survival in DLT recipients was 79.9%, 65.3%, and 61.6%,
respectively. Also, several studies found no difference in
the rates of acute rejection, perioperative bleeding, 
vascular complications or biliary complications
between domino transplant recipients and cadaveric
transplant recipients (8,41,42,43).
From July 2001 to October 2020, 337 patients
underwent a DLT with a FAP liver in our center. The 
population was composed of 271 men (80.3%) and 66
women (19.7%) with a median age at the time of LT of
57 years. Main indications for the DLT recipients are
described in table 1. After a median follow-up of 108
Figure 1 - a: Abdominal cavity after hepatectomy in a FAP liver donor; b: Orifices of the hepatic veins; 
c,d: “neo” suprahepatic inferior vena cava 
a b
c d
Table 1 - Demographic characteristics and indications 
for liver transplantation in FAP liver recipients
FAP liver recipients 
(n=337)
Demographic characteristics
Female sex, n (%) 66 (19.7%)
Age (years), median [IQR] 57 [10]
Main indications for liver transplantation, n (%)
Primary hepatic malignancy 147 (43.6%)
Alcoholic cirrhosis 81 (24%)
Cirrhosis secondary to hepatitis B and/or C 53 (15.7%)
Metastatic hepatic malignancy 6 (1.8%)
Retransplantation 15 (4.5%)
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months (35–163 months), 85 patients (25.2%) 
developed clinical signs of FAP disease, most commonly
neuropathic pain, lack of sensibility, diarrhea or weight
loss. 62 (18.4%) had disease confirmation after repeated
neurological assessment and electro-myography.
Amyloid deposition was demonstrated in 55 patients
either by labial salivary gland, sural nerve, rectal, renal
or fat biopsy (table 2). 20 of these patients with
acquired FAP underwent retransplantation with a
cadaveric donor liver. Although in 3 patients the 
symptoms worsened, 9 of the 20 patients (45%) 
reported some improvement. 
CONCLUSION
In the light of current knowledge, DLT remains a
good option in carefully selected patients. Given the
known risk of FAP disease transmission, the selection
of DLT recipients must consider the status of the
patient 7-8 years after transplantation, if a retrans-
plant is necessary. Since acquired polyneuropathy
occurs earlier than anticipated, DLT could be 
considered for extended indications and according to
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